Servier UK

Life through Discovery

Servier has a unique cultural heritage as an independent French research based Foundation. We invest only in therapeutic areas where there is a real unmet medical need and develop truly innovative drugs to improve the quality of people’s lives.  As a private research foundation, Servier has no shareholders and the freedom to prioritise research over profits.  Revenue generated by our medicines is used to fund ongoing research.

Servier was created in 1954, and in 1963 Servier UK was the first subsidiary to open, with just two employees.

Our Goal

We are proud to be part of the Servier Research Group, whose fundamental principles have guided us to exceptional success throughout the past 50 years. The Group’s key goal, the discovery of innovative drugs and their development for use by the worldwide healthcare community, is a long-term undertaking marked by challenges that are scientific, human, industrial and financial.

Servier focuses its research in specific areas including:

Cardiovascular disease (angina, blood pressure, heart disease)

Metabolic disease (diabetes)

Rheumatology (osteoporosis)

Mental Health (depression)

Oncology (cancer)

Our current portfolio of medicinal products available in the UK is:

Coversyl Arginine (perindopril)

Coversyl Arginine Plus (perindopril and indapamide)

Diamicron MR (gliclazide)

Lonsurf (trifluridine/tipiracil)

Natrilix SR (indapamide)

Pixuvri (pixantrone)

Procoralan (ivabradine hydrochloride)

Protelos (strontium ranelate)

Valdoxan (agomelatine)


UK14WEB0013(2) DoP: October 2017